Teva Pharma Industries Ltd ADR (TEVA)

Exchange: USA Stocks • Country: Israel • Currency: USD • Type: Common Stock • ISIN: US8816242098

Generic Medicines, Specialty Medicines, Biopharmaceuticals

Teva Pharmaceutical Industries Limited is a global leader in the development, manufacturing, and distribution of a wide range of pharmaceutical products. The company's portfolio includes generic medicines, specialty medicines, and biopharmaceutical products that cater to various therapeutic areas, such as central nervous system, respiratory, and oncology.

Teva's generic medicines come in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. The company also offers sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms, as well as generic products with medical devices and combination products.

The company has a strong focus on research and development, with a pipeline of innovative products and technologies. Its active pharmaceutical ingredients and contract manufacturing services enable other pharmaceutical companies to develop and produce their own products. Teva's out-licensing platform offers a portfolio of products to other companies, further expanding its reach and impact.

Teva's specialty medicines include a range of branded products, such as BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-Hodgkin's lymphoma. The company also offers GRANIX, TRISENOX, LONQUEX, and TEVAGRASTIM/RATIOGRASTIM, among others. Additionally, Teva provides COPAXONE for the treatment of relapsing forms of multiple sclerosis, AJOVY for the preventive treatment of migraine in adults, and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia.

In the respiratory space, Teva offers ProAir RespiClick inhalation powder, QVAR for the treatment of asthma, BRALTUS, a long-acting muscarinic antagonist, CINQAIR/CINQAERO injection, and DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator. The company also provides AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder.

Teva's over-the-counter (OTC) products are marketed under various brand names, including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA. The company has collaboration agreements with several partners, including MedinCell, Sanofi, Alvotech, and Biolojic Design Ltd., as well as a license agreement with MODAG GmbH.

With a rich history dating back to 1901, Teva Pharmaceutical Industries Limited is headquartered in Tel Aviv, Israel, and has established itself as a leading global pharmaceutical company. The company's commitment to innovation, quality, and patient care has enabled it to make a significant impact in the lives of millions of people around the world.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Teva Pharma Industries Ltd ADR (TEVA)

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Teva Pharma Industries Ltd ADR (TEVA)

TEVA Stock Overview

Market Cap in USD 19,538m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1990-03-26

TEVA Stock Ratings

Growth 5y 38.7
Fundamental -1.24
Dividend 3.56
Rel. Performance vs Sector 6.99
Analysts 3.92/5
Fair Price Momentum 18.85 USD
Fair Price DCF 28.39 USD

TEVA Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 71.2%

TEVA Growth Ratios

Growth 12m 122.57%
Growth Correlation 12m 78%
Growth Correlation 3m 58%
CAGR 5y 15.48%
CAGR/Mean DD 5y 0.63
Sharpe Ratio 12m 3.32
Alpha vs SP500 12m 90.31
Beta vs SP500 5y weekly 1.22
ValueRay RSI 40.06
Volatility GJR Garch 1y 35.45%
Price / SMA 50 9.21%
Price / SMA 200 39.7%
Current Volume 7845.2k
Average Volume 20d 8172.1k

External Links for TEVA Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of TEVA stocks?
As of June 22, 2024, the stock is trading at USD 16.96 with a total of 7,845,159 shares traded.
Over the past week, the price has changed by -1.17%, over one month by +2.23%, over three months by +23.35% and over the past year by +127.04%.
What are the forecast for TEVA stock price target?
According to ValueRays Forecast Model, TEVA Teva Pharma Industries Ltd ADR will be worth about 20.5 in June 2025. The stock is currently trading at 16.96. This means that the stock has a potential upside of +20.58%.
Issuer Forecast Upside
Wallstreet Target Price 18.5 9.08
Analysts Target Price 10.6 -37.7
ValueRay Target Price 20.5 20.6